Sugi Predict

Sugi Predict / Compounds / SCHEMBL489156

SCHEMBL489156

SCHEMBL489156

COC(=O)[C@@H]1C[C@H](N)CN1C(=O)OC(C)(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 4/20 0.65
▸ MMP2 P08253 4/20 0.65
▸ CYP1A2 P05177 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ HTRA1 Q92743 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ P2RX3 P56373 1/20 0.35
▸ PEPD P12955 2/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ XPNPEP1 Q9NQW7 1/20 0.34
▸ MMP1 P03956 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL670493 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL2328122 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL1267438 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL1267008 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL670494 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL25181712 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL1545946 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
SCHEMBL7729511 1.00 ANPEP (0.65) ANPEPMMP2CYP1A2POLBCYP3A4
Hydrochloric Acid SCHEMBL1412084 0.98 ANPEP (0.63) ANPEPMMP2CYP1A2POLBCYP3A4
Hydrochloric Acid SCHEMBL2347422 0.98 ANPEP (0.63) ANPEPMMP2CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109406685-B High performance liquid chromatography method for separating carfilzomib and isomers thereof 湖南泰新医药科技有限公司 2021-05-25 — — CN claimed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 — — EP disclosed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 — — EP disclosed
EP-4739670-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-13 — — EP disclosed
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-05-07 — — US disclosed
US-20260092056-A1 MELANOCORTIN-4 RECEPTOR AGONISTS LG CHEMICAL LTD (KR) 2026-04-02 — — US disclosed
US-20260070927-A1 INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2026-03-12 — — US disclosed
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-02-12 — — US disclosed
US-12516047-B2 Melanocortin-4 receptor agonists LG CHEM, LTD. (KR) 2026-01-06 — — US disclosed
US-12390446-B2 Proline-based neuropeptide FF receptor modulators RESEARCH TRIANGLE INSTITUTE (US) 2025-08-19 — — US disclosed
US-7300929-B2 Mediators of hedgehog signaling pathways, compositions and uses related thereto CURIS, INC. (US) 2007-11-27 — — US disclosed
US-7300929-B2 Mediators of hedgehog signaling pathways, compositions and uses related thereto CURIS, INC. (US) 2007-11-27 — — US disclosed
WO-2007104162-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2007-09-20 — — WO disclosed
WO-2007104162-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2007-09-20 — — WO disclosed
US-20050245538-A1 Proline derivatives and use thereof as drugs KITAJIMA HIROSHI 2005-11-03 — — US disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 — — US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
EP-0289911-B1 PYRROLIDINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-06-16 — — EP disclosed
US-4916152-A THROMBOXANE A2 ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-04-10 — — US disclosed
EP-0289911-A2 Pyrrolidine derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-11-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390446-B2 Proline-based neuropeptide FF receptor modulators NPFFR1, NPFFR2, NPBWR1 ANPEP 93/4885MMP2 2459/4885CYP1A2 4337/4885
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS ANPEP 3785/4885MMP2 3266/4885CYP1A2 3305/4885
US-20050245538-A1 Proline derivatives and use thereof as drugs DPP4, DPP3, DPP7 ANPEP 16/4885MMP2 45/4885CYP1A2 1383/4885
US-20260070927-A1 INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE MALT1, CCR1, CCR6 ANPEP 4174/4885MMP2 4740/4885CYP1A2 449/4885
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS ANPEP 4117/4885MMP2 2985/4885CYP1A2 2360/4885
US-20260092056-A1 MELANOCORTIN-4 RECEPTOR AGONISTS MC5R, MC4R, MC3R ANPEP 1620/4885MMP2 2674/4885CYP1A2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.